517 results on '"Murphy, Maureen E."'
Search Results
2. Functional interplay among thiol-based redox signaling, metabolism, and ferroptosis unveiled by a genetic variant of TP53
3. Shifting the paradigms for tumor suppression: lessons from the p53 field
4. RETRACTED ARTICLE: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance
5. Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53
6. Editorial: Double-edged swords: important factors connecting metabolic disorders and cancer development -- from basic research to translational applications, volume II.
7. FIGURE 6 from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
8. FIGURE 4 from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
9. Figure S1 from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
10. The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
11. Data from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
12. FIGURE 1 from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
13. FIGURE 7 from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
14. Table S1 and S2 from The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
15. Data from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
16. Table S1 and S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
17. Data from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
18. Figure S2 from The African-Centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
19. Table S3 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
20. Supplementary Figures S1-S8 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
21. p53 Oligomerization Domain Mutants: A New Class of Mutants That Retain “License to Kill”
22. An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
23. Retraction Note: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance
24. Fatty acid transport protein 2 reprograms neutrophils in cancer
25. Figure S8 from Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis
26. Data from Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis
27. Data from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
28. Supplemental Figure 2 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
29. Supplemental Figure 3 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
30. Supplemental Table 1 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
31. Supplemental Figures S1-S7 and Supplemental Table S1 from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles
32. Data from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles
33. Supplementary Figure 3 from A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent
34. Supplemental Figure 5 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
35. Data from The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch–Nodal Axis
36. Supplementary Figure, Figure Legends, Tables and Material and Methods from The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch–Nodal Axis
37. Supplemental Figure legends from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
38. Supplemental Table 2 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
39. Chemical Methods from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles
40. Data from A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent
41. Supplemental Figure 4 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
42. Supplemental Figure 1 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
43. Supplementary Figure Legend from A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent
44. Supplemental Figure 6 from Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes
45. Supplementary Figure 1 from A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent
46. Supplementary Figure 2 from A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent
47. Suppl. Figure 8 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors
48. Data from A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers
49. Suppl. Figure 1 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors
50. Suppl. Figure 5 from HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.